Veristat Executive and Leadership Team

Kim McLean Boericke, the Chief Executive Officer at Veristat, directs the company's overarching strategy and operational execution. Boericke guides Veristat's mission to support pharmaceutical, biotechnology, and medical device companies through complex clinical trials and regulatory submissions. This leadership involves fostering a science-focused culture that prioritizes data integrity and patient well-being. Boericke ensures alignment across all departments, driving innovation in clinical research methodologies. The Chief Executive Officer's focus remains on enhancing Veristat's capabilities to accelerate drug development timelines and achieve successful regulatory outcomes for clients. Kim McLean Boericke's strategic vision shapes the organization's growth trajectory and market positioning within the competitive CRO landscape. This role demands a deep understanding of global regulatory environments and a commitment to scientific excellence, ensuring Veristat remains a trusted partner in bringing life-changing therapies to market.

David Koster, the Co-Founder & Chief Executive Officer at Veristat, provides foundational leadership and strategic direction. Koster's role centers on establishing and maintaining Veristat's core values and long-term vision, particularly in supporting clinical trials and regulatory submissions. This involves overseeing the company's expansion and ensuring its scientific approach remains at the forefront of the industry. Koster's leadership influences the development of services tailored to pharmaceutical, biotechnology, and medical device sectors. The Co-Founder & Chief Executive Officer's commitment extends to cultivating strong client relationships and fostering an environment of continuous improvement. David Koster's influence is critical in navigating the evolving landscape of clinical research, ensuring Veristat consistently delivers high-quality support and drives successful outcomes for its partners. This executive function is key to upholding the company's reputation for scientific integrity and operational excellence.

Joshua Korth, the Chief Financial Officer at Veristat, manages the organization's financial health and strategic fiscal planning. Korth oversees all financial operations, including budgeting, forecasting, and resource allocation, ensuring robust financial controls are in place. This executive function is vital for supporting Veristat's growth initiatives and its mission as a science-focused clinical research organization. The Chief Financial Officer's responsibilities extend to optimizing financial performance and driving profitability, enabling continued investment in innovative clinical trial support and regulatory submission services. Joshua Korth ensures financial strategies align with the company's commitment to pharmaceutical, biotechnology, and medical device clients. This leadership role is critical for maintaining financial stability and supporting the long-term sustainability of Veristat's operations and its capacity to deliver exceptional client value.

John Balser, the President at Veristat, drives operational excellence and strategic execution across the organization. Balser's leadership focuses on enhancing Veristat's capabilities in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. This role involves overseeing the integration of scientific expertise with efficient operational processes to deliver superior client outcomes. The President ensures that Veristat's service offerings remain innovative and responsive to industry demands, fostering a culture of collaboration and scientific rigor. John Balser's strategic oversight is crucial for managing the company's global operations and expanding its market reach. This executive position is instrumental in translating Veristat's mission into tangible results, ensuring the organization consistently meets and exceeds client expectations in the complex field of clinical research.